跳转至内容
Merck
CN
  • Suppression of the DHX9 helicase induces premature senescence in human diploid fibroblasts in a p53-dependent manner.

Suppression of the DHX9 helicase induces premature senescence in human diploid fibroblasts in a p53-dependent manner.

The Journal of biological chemistry (2014-07-06)
Teresa Lee, Domenic Di Paola, Abba Malina, John R Mills, Amina Kreps, Frank Grosse, Hengli Tang, Maria Zannis-Hadjopoulos, Ola Larsson, Jerry Pelletier
摘要

DHX9 is an ATP-dependent DEXH box helicase with a multitude of cellular functions. Its ability to unwind both DNA and RNA, as well as aberrant, noncanonical polynucleotide structures, has implicated it in transcriptional and translational regulation, DNA replication and repair, and maintenance of genome stability. We report that loss of DHX9 in primary human fibroblasts results in premature senescence, a state of irreversible growth arrest. This is accompanied by morphological defects, elevation of senescence-associated β-galactosidase levels, and changes in gene expression closely resembling those encountered during replicative (telomere-dependent) senescence. Activation of the p53 signaling pathway was found to be essential to this process. ChIP analysis and investigation of nascent DNA levels revealed that DHX9 is associated with origins of replication and that its suppression leads to a reduction of DNA replication. Our results demonstrate an essential role of DHX9 in DNA replication and normal cell cycle progression.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
单克隆抗 β-肌动蛋白抗体 小鼠抗, clone AC-15, ascites fluid
Sigma-Aldrich
抗磷酸组蛋白H2A.X(Ser139)抗体,克隆JBW301, clone JBW301, Upstate®, from mouse
Sigma-Aldrich
亚甲蓝, certified by the BSC
Sigma-Aldrich
亚甲蓝 溶液, concentrate according to Ehrlich, concentrated, aqueous solution
Sigma-Aldrich
亚甲蓝 溶液, 0.05 wt. % in H2O
Sigma-Aldrich
亚甲蓝 溶液, suitable for microscopy
Sigma-Aldrich
亚甲蓝 溶液, suitable for microbiology
Supelco
4-叔辛基苯酚单氧化物 溶液, 10 μg/mL in acetone, analytical standard
Sigma-Aldrich
MISSION® esiRNA, targeting human TP53